| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
TherapeuticsMD, Inc.$2.03
+0.09 (+4.64%)
C 45Pipeline Score Undervalued Pharma · Clinical
Market Cap
24.54 M
EPS
0.02
P/E Ratio
137.66 $
Value Trade
88.44 K
SEC Financials
Q1 2026Dilution Risk
Revenue
724.00 K
Operating CF
944.00 K
Total Assets
37.58 M
Total Liabilities
10.61 M
Equity
26.97 M
D/E Ratio
12,345
6 %
Week
1.92 %
1 Month
-7.42 %
3 Month
12.17 %
6 Month
-96.58 %
5 Year
-99.88 %
All Time
Cash Data
Cash Position
8.42 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
28.48 K
52 Week Range
0.98 - 2.95
% held by Insiders
6.87 %
% held by Institutions
33.96 %
Enterprise Value
21.95 M
Total Shares
11.58 M
Short %
0.52 %
Float Shares
8.29 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for TherapeuticsMD, Inc.
472Total events
0Upcoming
132Tier-1 (high impact)
2012 – 2026Coverage
Event history 2
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
●Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | TX-004HR (estradiol vaginal insert) | PDUFA Date | PDUFA | CRL | – | – | – |
— | TX-004HR (estradiol vaginal insert) | PDUFA Date | PDUFA | CRL | – | – | – |
— | TX-004HR (estradiol vaginal insert) | PDUFA Date | PDUFA | CRL | – | – | – |
Drug Pipeline Intelligence
C45
Pipeline Score $142M
Pipeline ValueUndervalued
Valuation Signal2
Drugs Scored5.8x
rNPV / MCap Top 65%
Micro Cap (rank 320 of 912)
Percentile RankTherapeuticsMD, Inc. carries a moderate pipeline score (45/100), with $1.9B risk-adjusted pipeline value, led by Estradiol in Menopause (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Estradiol Small molecule | Menopause | Phase 3 | NCT02449902 | 60% | $1.9B | COMPLETED | 1,915 | - | - | Sep 1, 2013 | - | Dec 14, 2015 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TX-001HR | moderate to severe vasomotor symptoms (VMS) | Phase 3 | 2016-12-05 | doses: estradiol 1 mg, progesterone 100 mg, n 416, estradiol 0.5 mg, progesterone 100 mg, n 423, estradiol 0.5 mg, progesterone 50 mg, n 421, estradiol 0.25 mg, progesterone 50 mg, n 424; adverse events: headache, nasopharyngitis, breast tenderness, upper respiratory infection Read More | TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR - TX-001HR, the Read More | |
TX-001HR | moderate to severe vasomotor symptoms (VMS) | Phase 3 | 2016-12-05 | doses: estradiol 1 mg, progesterone 100 mg, n 416, estradiol 0.5 mg, progesterone 100 mg, n 423, estradiol 0.5 mg, progesterone 50 mg, n 421, estradiol 0.25 mg, progesterone 50 mg, n 424; adverse events: headache, nasopharyngitis, breast tenderness, upper respiratory infection Read More | TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR - TX-001HR, the Read More | |
TX-001HR | moderate to severe vasomotor symptoms (VMS) | Phase 3 | 2016-12-05 | doses: estradiol 1 mg, progesterone 100 mg, n 416, estradiol 0.5 mg, progesterone 100 mg, n 423, estradiol 0.5 mg, progesterone 50 mg, n 421, estradiol 0.25 mg, progesterone 50 mg, n 424; adverse events: headache, nasopharyngitis, breast tenderness, upper respiratory infection Read More | TherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR - TX-001HR, the Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TXMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TXMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TXMDTherapeuticsMD Announces First Quarter 2026 Financial Results
TherapeuticsMD has announced its financial results for the first quarter of 2026. However, the article does not provide specific details regarding the performance metrics or any significant developments related to the company's operations. The lack of detailed information limits the insight into the company's current standing.
Read more →TXMD▼ -5.2%on this news
TherapeuticsMD Announces Full Year 2025 Financial Results
TherapeuticsMD has announced its financial results for the full year 2025. The article provides an overview of the company's performance, but lacks detailed insights into specific financial metrics or strategic developments. Further analysis may be needed to understand the implications of these results on the company's future.
Read more →TXMDTherapeuticsMD Announces Third Quarter 2025 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)
TherapeuticsMD, Inc. has announced its financial results for the third quarter of 2025, showing a transition from a women's healthcare company to a pharmaceutical royalty model. This change entails a focus on collecting royalties rather than engaging in research and development. The company also highlighted the continued exploration of strategic alternatives amidst various operational risks, including commercialization challenges and ongoing disputes with partners.
Read more →TXMDTherapeuticsMD Announces Second Quarter 2025 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)
TherapeuticsMD, Inc. recently reported its financial results for the second quarter of 2025, marking a shift in its business model from a women's healthcare company to a pharmaceutical royalty entity. Despite the change, the company faces several challenges, including uncertainties surrounding its licensees' success and the winding down of its previous operations. The exploration of strategic alternatives, such as acquisitions or mergers, may offer potential pathways to enhance shareholder value. However, these efforts come with inherent risks, particularly relating to operational transition and market performance.
Read more →TXMDTherapeuticsMD Announces First Quarter 2025 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)
TherapeuticsMD, Inc. announced its financial results for Q1 2025, revealing a loss from continuing operations and an ongoing transition to a pharmaceutical royalty company after previously focusing on women's healthcare. The company is not engaging in research and development anymore, instead collecting royalties from licensees. This shift in business strategy raises uncertainties surrounding the company's future performance and potential challenges in retaining its Nasdaq listing. Additionally, disputes with Mayne Pharma add further risks to the company's outlook.
Read more →TXMDTherapeuticsMD Announces Full Year 2024 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)
TherapeuticsMD, Inc. reported its financial results for the full year ending December 31, 2024, indicating a net loss from continuing operations. The company has shifted its focus from women's healthcare to a pharmaceutical royalty model, ending its research and development activities. This transition raises concerns about future business opportunities and reliance on the success of licensees to drive revenue. Forward-looking statements highlight the company's exploration of strategic alternatives in the face of significant operational changes.
Read more →TXMDTherapeuticsMD Announces Third Quarter 2024 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)
TherapeuticsMD, Inc. announced its financial results for the third quarter of 2024, highlighting a transition from a women's healthcare firm to a pharmaceutical royalty company. The company reported license and service revenues but is ceasing its research and development efforts. TherapeuticsMD is currently exploring strategic alternatives, which may include mergers or acquisitions. The firm faces risks regarding the commercialization success of its licensees and maintaining its Nasdaq listing.
Read more →TXMDTherapeuticsMD Announces Second Quarter 2024 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)
TherapeuticsMD, Inc. reported its second quarter 2024 financial results, showing net losses from continuing operations. The company, now operating as a pharmaceutical royalty firm, has transitioned from its previous focus on women's healthcare. It is currently assessing various strategic alternatives, which may include acquisitions or other transactions, to enhance shareholder value. Ongoing challenges include the success of its licensees in commercializing products and the costs associated with winding down previous operations.
Read more →TXMDTherapeuticsMD Announces First Quarter 2024 Financial Results BOCA RATON, Fla.--(BUSINESS WIRE)
TherapeuticsMD, Inc. announced its financial results for the first quarter of 2024, marking a significant transition from a women's healthcare focus to a pharmaceutical royalty model. While the company is exploring strategic alternatives such as potential acquisitions and other business combinations, it faces substantial challenges as it has ceased research and development activities. Additionally, there are concerns over the commercial success of its licensees and the operational costs tied to winding down previous operations.
Read more →TXMDTherapeuticsMD Announces Full Year 2023 Financial Results Evaluation of strategic alternatives continues BOCA RATON, Fla.--(BUSINESS WIRE)
TherapeuticsMD, Inc. has announced its financial results for the full year ended December 31, 2023, while continuing to explore a variety of strategic alternatives aimed at maximizing shareholder value. Following its shift from a women's healthcare focus to a pharmaceutical royalty business model in December 2022, the company is no longer involved in research and development. The CEO, Marlan D. Walker, indicated that the company is committed to reviewing options such as acquisitions, mergers, or asset sales. The transition raises concerns regarding operational execution and financial stability as it relies on its licensees for revenue.
Read more →TXMDTherapeuticsMD Announces Third Quarter 2023 Financial Results Focus remains on cost control to maximize the value of our royalty assets Company announces evaluation of strategic alternatives
TherapeuticsMD reported its third quarter 2023 financial results, indicating a continued focus on cost control and maximizing the value of its royalty assets. The company, which has transitioned from a women's healthcare focus to primarily collecting pharmaceutical royalties, also announced an evaluation of strategic alternatives. Current financial results reflect a net loss from continuing operations, highlighting the challenges faced during this transition. The management team underscored their commitment to exploring potential strategic options to enhance shareholder value.
Read more →TXMDTherapeuticsMD Announces Second Quarter 2023 Financial Results
TherapeuticsMD reported its financial results for Q2 2023, highlighting a net loss from continuing operations. The company is transitioning from a women's healthcare focus to a royalty-based business model and is currently working on cost reduction. However, it faces uncertainties, particularly concerning the commercialization of its licensed products and ongoing operational wind-down costs.
Read more →TXMDTherapeuticsMD Announces First Quarter 2023 Financial Results
TherapeuticsMD (TXMD) announced its financial results for the first quarter of 2023, highlighting its transition from a women's healthcare company to a pharmaceutical royalty model. The company is winding down its former operations and focusing on cost reduction. This shift raises concerns about its ability to generate revenue and maintain stability. Additionally, TXMD's future performance is contingent on the success of its partner, Mayne Pharma, which adds further risk amid ongoing uncertainties.
Read more →TXMDTherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
TherapeuticsMD, Inc. reported its financial results for the full year 2022 and announced its transition to a virtual business model following a transaction with Mayne Pharma. During this process, TherapeuticsMD eliminated its commercial and manufacturing infrastructure and downsized to one full-time employee. The transaction included a $140 million upfront payment, as well as future royalties from the sale of its products. The company is actively seeking strategic avenues to enhance shareholder value despite operational downsizing and potential risks associated with future commercialization success.
Read more →TXMD▲ +11.8%on this news
TherapeuticsMD Completes Transaction to License its Products to Mayne Pharma - Mayne Pharma gains exclusive U.S. commercialization rights for TXMD s products and acquires certain assets - - TXMD received approximately $1
TherapeuticsMD has completed a transaction to license its products to Mayne Pharma, granting the latter exclusive commercialization rights in the U.S. TXMD received approximately $153.1 million at closing, which will be used to repay outstanding debts and redeem preferred stock. The deal also provides TXMD with the potential for additional milestone and royalty payments over the coming years. Several board members resigned as part of the transaction, raising concerns about future leadership stability.
Read more →TXMDUnaudited Pro Forma Condensed Consolidated Financial Information Overview Effective
Unaudited Pro Forma Condensed Consolidated Financial Information Effective December 30, 2022 (the Closing Date ), TherapeuticsMD, Inc., a Nevada corporation (the Company ), completed its previously announced transaction (the Transaction ) with Mayne Pharma LLC, a Delaware limit
Read more →TXMD▲ +15.1%on this news· ran to +34% by day 3
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma - TXMD to receive approximately $153.1 million in consideration at closing (including approximately $13.1 million for acquired net wo
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma - TXMD to receive approximately $153.1 million in consideration at closing (including approximately $13.1 million for acquired net working capital), up to approximately $42.6 million in minim
Read more →TXMD▼ -7.4%on this news· ran to -24% by day 3
TherapeuticsMD Announces Third Quarter 2022 Financial Results - Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year
TherapeuticsMD Announces Third Quarter 2022 Financial Results - Q3 total revenue of $20.9 million - - ANNOVERA TRx growth of 10% year-over-year - - Reduced operating expenses by $22 million year-over-year - BOCA RATON, Fla. - November 14, 2022 - TherapeuticsMD, Inc. ("TXMD" o
Read more →TXMD▲ +6.2%on this news
TherapeuticsMD Announces Additional $7 Million Private Placement Maturity Date of Financing Agreement Extended to
TherapeuticsMD Announces Additional $7 Million Private Placement Maturity Date of Financing Agreement Extended to November 30, 2022 BOCA RATON, Fla. October 31, 2022 TherapeuticsMD, Inc. (NASDAQ: TXMD), ( TherapeuticsMD or the Company ) an innovative, leading women s healthcar
Read more →TXMD▼ -7.5%on this news
TherapeuticsMD Announces $7 Million Private Placement Maturity Date of Financing Agreement Extended to
TherapeuticsMD Announces $7 Million Private Placement Maturity Date of Financing Agreement Extended to October 31, 2022, with the Ability to Extend to November 30, 2022, if Additional BOCA RATON, Fla. October 3, 2022 TherapeuticsMD, Inc. (NASDAQ: TXMD), ( TherapeuticsMD or the
Read more →TXMD▲ +5.5%on this news
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers - Robust Strategic Alternatives Process Continues
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers - Robust Strategic Alternatives Process Continues - BOCA RATON, Fla. September 12, 2022 TherapeuticsMD, Inc. (NASDAQ: TXMD), ( TherapeuticsMD or the Company ) an innovative,
Read more →TXMDTherapeuticsMD Announces Second Quarter 2022 Financial Results - Quarterly total net revenue of $28.6 million - - ANNOVERA TRx of 9,329, an increase of 28% over Q2 2021 - - Conference call scheduled for 8:30 a.m. ET toda
TherapeuticsMD Announces Second Quarter 2022 Financial Results - Quarterly total net revenue of $28.6 million - - ANNOVERA TRx of 9,329, an increase of 28% over Q2 2021 - - Conference call scheduled for 8:30 a.m. ET today - BOCA RATON, Fla. - August 15, 2022 - TherapeuticsMD,
Read more →TXMD▲ +36.6%on this news· ran to +52% by day 1
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital Company Also Reaches Agreement with Sixth Street Partners to Extend the Maturity Date of its Financing Agreement to
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital Company Also Reaches Agreement with Sixth Street Partners to Extend the Maturity Date of its Financing Agreement to September 30, 2022 with the Ability to Extend to November 30, 2022 if Additional Capital
Read more →TXMD▲ +364%on this news
TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD
TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD BOCA RATON, Fla. - May 31, 2022 -- TherapeuticsMD, Inc. (NASDAQ: TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women's health
Read more →TXMD▲ +36.6%on this news
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA - ANNOVERA is the only FDA-approved procedure-free, long-lasting, reversible birth contro
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA - ANNOVERA is the only FDA-approved procedure-free, long-lasting, reversible birth control - - With this approval, the Company expects a significan
Read more →TXMDTherapeuticsMD Announces First Quarter 2022 Financial Results - Quarterly total net product revenue of $19.3 million - - ANNOVERA TRx of 8,014, an increase of 27% over Q1 2021 - - Announced and completed vitaCare divesti
TherapeuticsMD Announces First Quarter 2022 Financial Results - Quarterly total net product revenue of $19.3 million - - ANNOVERA TRx of 8,014, an increase of 27% over Q1 2021 - - Announced and completed vitaCare divestiture in five weeks - - Conference call scheduled for 4:3
Read more →TXMDTherapeuticsMD completes the divestiture of vitaCare Prescription Services to GoodRx in a cash transaction valued at $150 million
TherapeuticsMD completes the divestiture of vitaCare Prescription Services to GoodRx in a cash transaction valued at $150 million BOCA RATON, Fla. - April 14, 2022 -- TherapeuticsMD, Inc. (NASDAQ: TXMD), ("TXMD" or the "Company") an innovative, leading women's healthcare company
Read more →TXMD▼ -27.5%on this news
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results - Reached definitive agreement to fully divest vitaCare business unit enabling greater focus on achieving leadership position in women's healthcare - - Amend
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results - Reached definitive agreement to fully divest vitaCare business unit enabling greater focus on achieving leadership position in women's healthcare - - Amended credit terms with Sixth Street in support of a new capi
Read more →TXMD▲ +43.1%on this newsshared move
TherapeuticsMD Enters into a Definitive Agreement to Divest vitaCare to GoodRx GoodRx has agreed to acquire vitaCare for $150 million in cash, with an additional $7 million consideration contingent upon vitaCare's financ
TherapeuticsMD Enters into a Definitive Agreement to Divest vitaCare to GoodRx GoodRx has agreed to acquire vitaCare for $150 million in cash, with an additional $7 million consideration contingent upon vitaCare's financial performance through 2023 BOCA RATON, Fla.--(BUSINESS W
Read more →TXMDU.S. Food and Drug Administration (FDA) Responds to Request from TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA - FDA determined that it could not approve proposed revisions to the manufacturi
U.S. Food and Drug Administration (FDA) Responds to Request from TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA - FDA determined that it could not approve proposed revisions to the manufacturing testing limits requested through the Supplemental New Dr
Read more →TXMDTherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA (Estradiol and Progesterone) - Allowing for a
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA (Estradiol and Progesterone) - Allowing for a May 25, 2032 Generic Entry Date BOCA RATON, FL -- BUSINESS WIRE -December 8, 2021 -- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's healthcare
Read more →TXMDHugh O'Dowd: Thank you, everyone, for a wonderful morning. We look forward to taking further follow-up. We wish you all a very good day. Take care and be well, and Happy Veterans Day. Operator: Ladies and gentlemen, this
Operator: Good morning, ladies and gentlemen. Thank you for joining us for the TherapeuticsMD Third Quarter 2021 Financial Results Conference Call. (Operator Instructions) I would now like to turn the call over to Lisa Wilson, Investor Relations for TherapeuticsMD. Lisa? Lisa W
Read more →TXMDTherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer - Mr. O'Dowd to succeed Robert G. Finizio, effective on or before
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O'Dowd, as Chief Executive Officer - Mr. O'Dowd to succeed Robert G. Finizio, effective on or before December 31, 2021 - - Mr. Finizio appointed Vice Chair of the Board - BOCA RATON, Fla. - Nove
Read more →TXMDTherapeuticsMD Announces Appointment of Hugh O'Dowd as President O'Dowd brings 25+ years of experience in senior leadership roles with leading pharmaceutical companies
TherapeuticsMD Announces Appointment of Hugh O'Dowd as President O'Dowd brings 25+ years of experience in senior leadership roles with leading pharmaceutical companies - BOCA RATON, Fla. - August 8, 2021 - TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's heal
Read more →TXMD▼ -6.7%on this newsshared move
TherapeuticsMD Announces Second Quarter 2021 Financial Results - 2Q21 total net product revenue increased by 17% over 1Q21 to $23 million - - ANNOVERA prescription growth supported by improved acces
TherapeuticsMD Announces Second Quarter 2021 Financial Results - 2Q21 total net product revenue increased by 17% over 1Q21 to $23 million - - ANNOVERA prescription growth supported by improved access to providers and increased telemedicine options for patients - - Prescription
Read more →TXMDTherapeuticsMD Announces First Quarter 2021 Financial Results - 1Q21 total net revenue increased to $19.9 million - - 1Q21 total net product revenue increased 60% to $19.6 million compared to 1Q20 -
TherapeuticsMD Announces First Quarter 2021 Financial Results - 1Q21 total net revenue increased to $19.9 million - - 1Q21 total net product revenue increased 60% to $19.6 million compared to 1Q20 - - ANNOVERA prescriptions continue to grow with increasing consumer support and
Read more →TXMDTherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results - Full-year 2020 total net product revenue increased 84% to $62.9 million compared to 2019 - - 4Q20 total net product rev
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces Fourth Quarter and Full-Year 2020 Financial Results - Full-year 2020 total net product revenue increased 84% to $62.9 million compared to 2019 - - 4Q20 total net product revenue increased 30% to $22.6 million compared to 3Q2
Read more →TXMDBuilding the Premier Women's Health Company January 2021 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we," "our," or the "Company") may contain forward - looking statements .
TherapeuticsMD, Inc. 8-K Building the Premier Women's Health Company January 2021 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we," "our," or the "Company") may contain forward - looking statements . Forward - looking statements may
Read more →TXMDTherapeuticsMD Announces Third Quarter 2020 Financial Results - Significant growth in net revenue, net revenue per unit and prescriptions across product portfolio- -Total net revenue increased 80% t
Announces Third Quarter 2020 Financial Results - Significant growth in net revenue, net revenue per unit and prescriptions across product portfolio- -Total net revenue increased 80% to $19.3 million ANNOVERA net revenue increased 250% for 3Q20 compared - Menopausal products
Read more →TXMDFOR INVESTOR PRESENTATION PURPOSES ONLY. Corporate Presentation
TherapeuticsMD, Inc. 8-K FOR INVESTOR PRESENTATION PURPOSES ONLY. Corporate Presentation September 14, 2020 FOR INVESTOR PRESENTATION PURPOSES ONLY. Forward - Looking Statements 2 This presentation by TherapeuticsMD, Inc . (referred to as "we," "our," or "the Company") may cont
Read more →TXMDTherapeuticsMD Announces Second Quarter 2020 Financial Results - 2Q20 total net product revenue of $10.7 million resilient despite COVID-19 pandemic - - ANNOVERA prescriptions increased approximatel
TherapeuticsMD, Inc. 8-K Announces Second Quarter 2020 Financial Results - 2Q20 total net product revenue of $10.7 million resilient despite COVID-19 pandemic - - ANNOVERA prescriptions increased approximately 100% for the eight weeks ended July 24, 2020 over the previous ei
Read more →TXMDBuilding the Premier Women's Health Company June 2020 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we," "our," or "the Company") may contain forward - looking statements . Fo
TherapeuticsMD, Inc. 8-K Building the Premier Women's Health Company June 2020 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we," "our," or "the Company") may contain forward - looking statements . Forward - looking statements may in
Read more →TXMDTherapeuticsMD Announces Appointment of James C. D'Arecca as Chief Financial Officer and Retirement of Daniel A. Cartwright as Chief Financial Officer
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces Appointment of James C. D'Arecca as Chief Financial Officer and Retirement of Daniel A. Cartwright as Chief Financial Officer BOCA RATON, Fla., June 1, 2020 - TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthc
Read more →TXMDBuilding the Premier Women's Health Company BofA Securities Conference
Building the Premier Women's Health Company BofA Securities Conference May 13, 2020 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we," "our," or "the Company") may contain forward - looking statements . Forward - looking statements ma
Read more →TXMDTherapeuticsMD Announces First Quarter 2020 Financial Results - 1Q20 total net product revenue of $12.3 million exceeded Wall Street consensus- - Significantly reducing operating expenses, while m
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces First Quarter 2020 Financial Results - 1Q20 total net product revenue of $12.3 million exceeded Wall Street consensus- - Significantly reducing operating expenses, while maintaining goal of achieving EBITDA breakeven in 2021
Read more →TXMDTherapeuticsMD Further Strengthens Board with Appointment of New Independent Director - Karen L. Ling Appointed as Independent Director
TherapeuticsMD, Inc. 8-K TherapeuticsMD Further Strengthens Board with Appointment of New Independent Director - Karen L. Ling Appointed as Independent Director - April 22, 2020 - On behalf of the Board of Directors of TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leadi
Read more →TXMDTherapeuticsMD Provides COVID-19-Related Business Update - Strong preliminary first quarter 2020 total net revenue projected to be more than $11 million - - vitaCare Prescription Services model allo
TherapeuticsMD, Inc. 8-K TherapeuticsMD Provides COVID-19-Related - Strong preliminary first quarter 2020 total net revenue projected to be more than $11 million - - vitaCare Prescription Services model allowing the Company to connect with more than 80% of patients - - Impl
Read more →TXMDTherapeuticsMD Strengthens Board with Appointment of Industry Leaders - Paul Bisaro and Gail Naughton, Ph.D., Appointed as Independent Directors
THERAPEUTICSMD, INC. 8-K TherapeuticsMD Strengthens Board with Appointment - Paul Bisaro and Gail Naughton, Ph.D., Appointed as Independent Directors - March 24, 2020 - On behalf of the Board of Directors of TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women's
Read more →TXMDBuilding the Premier Women's Health Company Cowen Conference
TherapeuticsMD Inc. 8-K Building the Premier Women's Health Company Cowen Conference March 3, 2020 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements m
Read more →TXMDTherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results - 4Q19 Total Net Product Revenue of $15.9 Million Exceeded the Company's Financial Guidance- - Full-Year 2019 Total Net P
TherapeuticsMD Inc. 8-K TherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results - 4Q19 Total Net Product Revenue of $15.9 Million Exceeded the Company's Financial Guidance- - Full-Year 2019 Total Net Product Revenue of $34.1 Million at the Top End of Finan
Read more →TXMDBuilding the Premier Women's Health Company JP Morgan Conference January 2020 2 Forward - Looking Statements This presentation by TherapeuticsMD , Inc . (referred to as "we" and "our") may contain forward - looking state
TherapeuticsMD, Inc. 8-K Building the Premier Women's Health Company JP Morgan Conference January 2020 2 Forward - Looking Statements This presentation by TherapeuticsMD , Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking stateme
Read more →TXMDTherapeuticsMD Announces Amendment to Term Loan Financing Facility with TPG Sixth Street Partners - Amendment revises draw trigger for $50 million loan tranche previously tied to ANNOVERA TM designa
TherapeuticsMD, Inc. 8-K Announces Amendment to Loan Financing Facility with TPG Sixth Street Partners Amendment revises draw trigger for $50 million loan tranche previously tied to ANNOVERATM designation - RATON, Fla., December 30, 2019 - TherapeuticsMD, Inc. (NASDAQ: TXMD),
Read more →TXMDInvestor Update
TherapeuticsMD, Inc. 8-K 1 1 Investor Update December 18, 2019 Building a Premier Women's Health Portfolio 2 2 Forward - Looking Statements This presentation by TherapeuticsMD , Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking s
Read more →TXMDInvestor Presentation
TherapeuticsMD, Inc. 8-K 1 1 Investor Presentation November 19, 2019 Building a Premier Women's Health Portfolio 2 2 Forward - Looking Statements This presentation by TherapeuticsMD , Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - loo
Read more →TXMDTherapeuticsMD Announces Third Quarter 2019 Financial Results - 3Q19 Net Revenue (Product and License) Increased to $23.7 Million - - 3Q19 Product Net Revenue Increased 34% to $8.2 Million Compared
TherapeuticsMD, Inc. 8-K Announces Third Quarter 2019 Financial Results 3Q19 Net Revenue (Product and License) Increased to $23.7 Million - 3Q19 Product Net Revenue Increased 34% to $8.2 Million Compared to 2Q19- The Company Reaffirms 4Q19 Financial Guidance - Conference Cal
Read more →TXMDTherapeuticsMD Announces Estimated Third Quarter 2019 Financial Results
TherapeuticsMD Announces Estimated Third Quarter 2019 Financial Results BOCA RATON, Fla, October 23, 2019 TherapeuticsMD, Inc. (NASDAQ:TXMD) (the Company ) today announced its estimates of the financial results for the third quarter ended September 30, 2019. For the three mont
Read more →TXMDInvestor Presentation October 2019 Building a Premier Women's Health Portfolio 2 2 Forward - Looking Statements This presentation by TherapeuticsMD , Inc. (referred to as "we" and "our") may contain forward - looking sta
TherapeuticsMD, Inc. 8-K 1 Investor Presentation October 2019 Building a Premier Women's Health Portfolio 2 2 Forward - Looking Statements This presentation by TherapeuticsMD , Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - looking stat
Read more →TXMDInvestor Presentation September 2019 Building a Premier Women's Health Portfolio 2 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking st
TherapeuticsMD, Inc. 8-K 1 Investor Presentation September 2019 Building a Premier Women's Health Portfolio 2 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - looking sta
Read more →TXMDTherapeuticsMD Announces Second Quarter 2019 Financial Results -IMVEXXY Net Revenue $3.1 Million for the Second Quarter of 2019- -Total Net Revenue for the Second Quarter of 2019 Above Guidance at $
TherapeuticsMD, Inc. 8-K Announces Second Quarter 2019 Financial Results Net Revenue $3.1 Million for the Second Quarter of 2019- Net Revenue for the Second Quarter of 2019 Above Guidance at $6.1 Million- Raises Full-Year Net Revenue Guidance to Range of $29.45 Million to $34
Read more →TXMDINVESTOR UPDATE
TherapeuticsMD, Inc. 8-K 1 INVESTOR UPDATE July 9, 2019 ANNOVERA Building a Premier Women's Health Portfolio ( segesterone acetate and ethinyl estradiol vaginal system) 2 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") ma
Read more →TXMDNo Image 1
No Image 1 INVESTOR DAY June 10, 2019 ANNOVERA ( segesterone acetate and ethinyl estradiol vaginal system) 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - looking stateme
Read more →TXMDTherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA and IMVEXXY Outside the United States -Agreement leverages Theramex's extensive women's health c
TherapeuticsMD, Inc. 8-K TherapeuticsMD and Theramex Enter into Exclusive License and Supply Agreement to Commercialize BIJUVA and IMVEXXY Outside the United States -Agreement leverages Theramex's extensive women's health capabilities and infrastructure to the benefit of me
Read more →TXMDTherapeuticsMD Announces First Quarter 2019 Financial Results -BIJUVA Commercial Launch in April 2019- -Completed $300 Million Non-Dilutive Term Loan Financing Facility in April 2019- -IMVEXXY Conti
TherapeuticsMD, Inc. 8-K Announces First Quarter 2019 Financial Results Commercial Launch in April 2019- $300 Million Non-Dilutive Term Loan Financing Facility in April 2019- Continues Strong Positive Trends for Prescriptions and Patient Refills- Call Scheduled for 4:30 p.m.
Read more →TXMDINVESTOR UPDATE MAY 2019 ANNOVERA Building a Premier Women's Health Portfolio ( segesterone acetate and ethinyl estradiol vaginal system) 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred
TherapeuticsMD, Inc. 8-K 1 INVESTOR UPDATE MAY 2019 ANNOVERA Building a Premier Women's Health Portfolio ( segesterone acetate and ethinyl estradiol vaginal system) 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may cont
Read more →TXMDTherapeuticsMD Closes $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners -Leading Healthcare Investor Provides TherapeuticsMD with Strategic Growth Capital- - Non-
TherapeuticsMD, Inc. 8-K Closes $300 Million Non-Dilutive Term Loan Financing Facility TPG Sixth Street Partners Healthcare Investor Provides TherapeuticsMD with Strategic Growth Capital- Non-Dilutive Funding Supports the Launches of BIJUVATM and ANNOVERATM- RATON, Fla., Apr
Read more →TXMDTherapeuticsMD Signs Binding Commitment Letter for $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners - Leading Healthcare Investor Will Provide TherapeuticsMD wit
TherapeuticsMD, Inc. 8-K Signs Binding Commitment Letter for $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners Leading Healthcare Investor Will Provide TherapeuticsMD with Strategic Growth Capital - Additional Non-Dilutive Funding Will Suppo
Read more →TXMDIMVEXXY Update
TherapeuticsMD, Inc. 8-K IMVEXXY Update April 8, 2019 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may include, but are not limited to, statements
Read more →TXMDInvestor Presentation March 2019 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may includ
TherapeuticsMD, Inc. 8-K Investor Presentation March 2019 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may include, but are not limited to, statem
Read more →TXMDTherapeuticsMD Announces Fourth Quarter and Full-Year 2018 Financial Results -Successful Launch of IMVEXXY , Strong Positive Trends Continue for Prescriptions and Patient Refills- -BIJUVA Commercial
TherapeuticsMD, Inc. 8-K Announces Fourth Quarter and Full-Year 2018 Financial Results Launch of IMVEXXY , Strong Positive Continue for Prescriptions and Patient Refills- Commercial Launch on Track for the Second Quarter of 2019- Commercial Launch planned as Early as the Thi
Read more →TXMDInvestor Update February 4 , 2019 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may inclu
TherapeuticsMD, Inc. 8-K Investor Update February 4 , 2019 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may include, but are not limited to, state
Read more →TXMDInvestor Presentation January 2019 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may incl
TherapeuticsMD, Inc. 8-K Investor Presentation January 2019 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may include, but are not limited to, stat
Read more →TXMDForward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may include, but are not limited to, statemen
TherapeuticsMD, Inc. 8-K 1 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may include, but are not limited to, statements relating to our objectives, p
Read more →TXMDInvestor Update December 18 , 2018 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may incl
TherapeuticsMD, Inc. 8-K Investor Update December 18 , 2018 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may include, but are not limited to, stat
Read more →TXMDInvestor Presentation November 2018 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may inc
TherapeuticsMD, Inc. 8-K Investor Presentation November 2018 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may include, but are not limited to, sta
Read more →TXMDTherapeuticsMD Announces Third Quarter 2018 Financial Results -Strong early launch indicators for IMVEXXY - -BIJUVA commercial launch planned for 2Q 2019- -ANNOVERA commercial launch planned for 4Q
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces Third Quarter 2018 Financial Results early launch indicators for IMVEXXY - commercial launch planned for 2Q 2019- commercial launch planned for 4Q 2019- call scheduled for 4:30 p.m. ET today- RATON, Fla. - November 7, 2018 -
Read more →TXMDTherapeuticsMD Announces FDA Approval of TX-001HR: BIJUVA (Estradiol and Progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause - BIJUVA is the first and
TherapeuticsMD, Inc. 8-K Announces FDA Approval of TX-001HR: BIJUVA (Estradiol and Progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause - BIJUVA is the first and only FDA-approved hormone therapy of bio-identical estradiol in comb
Read more →TXMDInvestor Presentation October 2018 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may incl
TherapeuticsMD, Inc. 8-K Investor Presentation October 2018 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may include, but are not limited to, stat
Read more →TXMDTherapeuticsMD Enters Into Label Discussions for TX-001HR
TherapeuticsMD, Inc. 8-K Enters Into Label Discussions for TX-001HR RATON, Fla.-September 27, 2018- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the Company has entered into discussions with the U.S. Food and Drug Administ
Read more →TXMDInvestor Presentation September 2018 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may in
Investor Presentation September 2018 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may include, but are not limited to, statements relating to our o
Read more →TXMDInvestor Presentation August 2018 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may inclu
TherapeuticsMD, Inc. 8-K Investor Presentation August 2018 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - lookin g statements may include, but are not limited to, state
Read more →TXMDTherapeuticsMD Announces FDA Approval of ANNOVERA (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control - The first and only birth control approved as a vaginal system - - The fir
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces FDA Approval of ANNOVERA (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control - The first and only birth control approved as a vaginal system - - The first and only patient-controlled, procedure-free, lo
Read more →TXMDTherapeuticsMD Announces Second Quarter 2018 Financial Results -Imvexxy early experience program underway; national launch to commence
TherapeuticsMD, Inc. 8-K Announces Second Quarter 2018 Financial Results early experience program underway; national launch to commence August 6, 2018- target action date of October 28, 2018 for TX-001HR- RATON, Fla. - July 30, 2018 - TherapeuticsMD, Inc. (NASDAQ: TXMD), an
Read more →TXMDTherapeuticsMD Announces Draw Down of $75 Million Under Term Loan with MidCap Financial
TherapeuticsMD, Inc. 8-K Announces Draw Down of $75 Million Under Term Loan with MidCap Financial RATON, Fla. - June 7, 2018 - TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the company has completed the first draw down of $
Read more →TXMDInvestor Day
TherapeuticsMD, Inc. 8-K Investor Day June 4, 2018 THER - 0086 1/17 2 Introduction Robert Finizio Co - founder & Chief Executive Officer 3 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking stat
Read more →TXMDTherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY TM (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Sy
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXYTM (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom of VVA, due to Menopause -IMVEXXY's applicator-f
Read more →TXMDTherapeuticsMD Announces First Quarter 2018 Financial Results - $200 Million Non-Dilutive Term Loan Financing Completed to Support Commercialization - - PDUFA target action date of
THERAPEUTICSMD, INC. 8-K Announces First Quarter 2018 Financial Results $200 Million Non-Dilutive Term Loan Financing Completed to Support Commercialization - PDUFA target action date of May 29, 2018 for TX-004HR - PDUFA target action date of October 28, 2018 for TX-001HR -
Read more →TXMDTherapeuticsMD Enters Into Label Negotiations for TX-004HR
TherapeuticsMD, Inc. 8-K TherapeuticsMD Enters Into Label Negotiations RATON, Florida, April 11, 2018 - TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the Company has entered into negotiations with the U.S. Food and Drug Adm
Read more →TXMDTherapeuticsMD Announces Expansion of Board of Directors - Dr. Jane F. Barlow Appointed as Independent Director
TherapeuticsMD, Inc. 8-K Announces Expansion of Board of Directors Dr. Jane F. Barlow Appointed as Independent Director - RATON, Florida, April 2, 2018 - TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the appointment of Jane F.
Read more →TXMDTXMD Overview March 2018 THER - 0086 03/18 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements
TherapeuticsMD, Inc. 8-K TXMD Overview March 2018 THER - 0086 03/18 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements may include, but are not limited
Read more →TXMDTherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR - No Filing Review Issues Identified - - PDUFA target action date o
THERAPEUTICSMD, INC. 8-K TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR No Filing Review Issues Identified - PDUFA target action date of October 28, 2018 - RATON, Florida, March 8, 2018 - The
Read more →TXMDTherapeuticsMD Announces Fourth Quarter and Full Year 2017 Financial Results - PDUFA target action date of
THERAPEUTICSMD, INC. 8-K Announces Fourth Quarter and Full Year 2017 Financial Results PDUFA target action date of May 29, 2018 for TX-004HR - Acceptance of New Drug Application for TX-001HR expected in March 2018 - RATON, Fla. - February 20, 2018 - TherapeuticsMD, Inc. (NASD
Read more →TXMDTXMD Overview January 2018 THER - 0086 01/18 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statemen
TherapeuticsMD, Inc. 8-K TXMD Overview January 2018 THER - 0086 01/18 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements may include, but are not limit
Read more →TXMDTherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR - PDUFA target action date of
THERAPEUTICSMD, INC. 8-K Announces FDA Acceptance of New Drug Application and Drug User Fee Act (PDUFA) Date for TX-004HR PDUFA target action date of May 29, 2018 - RATON, Florida, Dec. 19, 2017 - TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company,
Read more →TXMDTXMD Overview November 2017 THER - 0086 11/17 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking stateme
TherapeuticsMD, Inc.8-K TXMD Overview November 2017 THER - 0086 11/17 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements may include, but are not limit
Read more →TXMDTherapeuticsMD Announces Third Quarter 2017 Financial Results - Resubmission of New Drug Application for TX-004HR expected in the coming weeks - - Submission of New Drug Application for TX-001HR exp
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces Third Quarter 2017 Financial Results - Resubmission of New Drug Application for TX-004HR expected in the coming weeks - - Submission of New Drug Application for TX-001HR expected in December 2017 - RATON, Fla. - November 6,
Read more →TXMDTXMD Overview October 2017 THER - 0086 10/17 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statemen
TherapeuticsMD, Inc. 8-K TXMD Overview October 2017 THER - 0086 10/17 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements may include, but are not limit
Read more →TXMDTherapeuticsMD Announces Move to Nasdaq Global Select Market
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces Move to Nasdaq Global Select Market RATON, Fla. - September 25, 2017 - TherapeuticsMD, Inc. (NYSE American: TXMD), an innovative women's healthcare company, today announced that it will voluntarily move its stock exchange listin
Read more →TXMDTXMD Overview September 2017 THER - 0086 9/17 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking stateme
TherapeuticsMD, Inc. 8-K TXMD Overview September 2017 THER - 0086 9/17 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements may include, but are not limi
Read more →TXMDTherapeuticsMD Provides TX-004HR Regulatory Update
TherapeuticsMD, Inc. 8-K Provides TX-004HR Regulatory Update RATON, Fla. - August 10, 2017 - TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced a regulatory update regarding the New Drug Application (NDA) for TX-004HR, the company'
Read more →TXMDTherapeuticsMD Announces Second Quarter 2017 Financial Results
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces Second Quarter 2017 Financial Results RATON, Fla. - August 3, 2017 - TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced its financial results for the quarter ended June 30, 2017.
Read more →TXMDTXMD Overview June 2017 THER - 0086 6/17 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements m
TherapeuticsMD, Inc. 8-K TXMD Overview June 2017 THER - 0086 6/17 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements may include, but are not limited t
Read more →TXMDTherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application - No approvability issues identified by FDA related to efficacy or CMC
TherapeuticsMD, Inc. 8-K TherapeuticsMD Receives Complete Response Letter from FDA for TX-004HR New Drug Application - No approvability issues identified by FDA related to efficacy or CMC - BOCA RATON, Fla. - May 8, 2017 - TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative
Read more →TXMDTherapeuticsMD Announces First Quarter 2017 Financial Results
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces First Quarter 2017 Financial Results BOCA RATON, Fla. - May 2, 2017 - TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, today announced its financial results for the quarter ended March 31, 2017
Read more →TXMDTherapeuticsMD Announces Fourth Quarter and Full-Year 2016 Financial Results - Pipeline of two late-stage product candidates advancing towards commercialization, with launch of TX-004HR expected in
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces Fourth Quarter and Full-Year 2016 Financial Results - Pipeline of two late-stage product candidates advancing towards commercialization, with launch of TX-004HR expected in fourth quarter 2017 pending regulatory to host confe
Read more →TXMDTXMD Overview January 2017 THER - 0086 1/17 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statement
TherapeuticsMD, Inc. 8-K TXMD Overview January 2017 THER - 0086 1/17 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements may include, but are not limite
Read more →TXMDTX - 001HR Supplemental Replenish Trial Design And Topline Phase 3 Results December 2016 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - loo
TherapeuticsMD, Inc. 8-K 1 TX - 001HR Supplemental Replenish Trial Design And Topline Phase 3 Results December 2016 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - loo
Read more →TXMDTherapeuticsMD Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR - TX-001HR, the
TherapeuticsMD, Inc. 8-K Announces Positive Top-Line Results from Pivotal Phase 3 Replenish Trial in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms (VMS) Treated with TX-001HR TX-001HR, the first bio-identical combination therapy of estradiol and progesterone
Read more →TXMDTherapeuticsMD Announces Third Quarter 2016 Financial Results - Topline phase 3 data for TX-001HR Replenish Trial on track for fourth quarter of 2016 - - TX-004HR PDUFA target action date of
TherapeuticsMD, Inc. - 8-K TherapeuticsMD Announces Third Quarter 2016 - Topline phase 3 data for TX-001HR Replenish Trial on track for fourth quarter of 2016 - - TX-004HR PDUFA target action date of May RATON, Fla. - Nov. 3, 2016 - TherapeuticsMD, Inc. (NYSE MKT: TXMD), an
Read more →TXMDTXMD Overview September 2016 THER - 0086 8/16 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking stateme
TherapeuticsMD, Inc. 8-K TXMD Overview September 2016 THER - 0086 8/16 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements may include, but are not limi
Read more →TXMDTherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy (TX-004HR) - PDUFA target action date of
TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for Yuvvexy (TX-004HR) PDUFA target action date of May 7, 2017 - RATON, Florida, Sept. 19, 2016 - TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women'
Read more →TXMDTXMD Overview August 2016 THER - 0086 8/16 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements
TXMD Overview August 2016 THER - 0086 8/16 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements may include, but are not limited to, statements relating t
Read more →TXMDTherapeuticsMD Announces Second Quarter 2016 Financial Results - New Drug Application submitted for Yuvvexy (TX-004HR) - - Topline phase 3 data for TX-001HR Replenish Trial on track for fourth quart
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces Second Quarter 2016 Financial Results - New Drug Application submitted for Yuvvexy (TX-004HR) - - Topline phase 3 data for TX-001HR Replenish Trial on track for fourth quarter of 2016 - August 4, 2016 - TherapeuticsMD, Inc.
Read more →TXMDTherapeuticsMD Announces New Drug Application Submission for Yuvvexy (TX-004HR)
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces New Drug Application Submission for Yuvvexy (TX-004HR) BOCA RATON, Fla., July 7, 2016 - TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, announced today that it has submitted its New Drug Appli
Read more →TXMDTherapeuticsMD Announces Filing Timeline for Yuvvexy (TX-004HR) New Drug Application
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces Filing Timeline for Yuvvexy (TX-004HR) New Drug Application BOCA RATON, Fla., June 29, 2016 - TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, announced today that it expects that the New Drug
Read more →TXMDTXMD Overview May 2016 THER - 0086 5/16 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements ma
TherapeuticsMD, Inc. 8-K TXMD Overview May 2016 THER - 0086 5/16 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements may include, but are not limited to
Read more →TXMDTherapeuticsMD Announces First Quarter 2016 Financial Results - NDA filing for TX-004HR planned by end of June 2016 - - Strong cash position of approximately $182 million to advance pipeline product
TherapeuticsMD, Inc. 8-K Announces First Quarter 2016 Financial Results - NDA filing for TX-004HR planned by end of June 2016 - - Strong cash position of approximately $182 million to advance pipeline products - RATON, Fla. - May 3, 2016 - TherapeuticsMD, Inc. (NYSE MKT: TX
Read more →TXMDREJOICE Trial Data Presentation
TherapeuticsMD, Inc. 8-K REJOICE Trial Data Presentation March 7, 2016 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements may include, but are not limi
Read more →TXMDTherapeuticsMD Announces Fourth Quarter and Full Year 2015 Financial Results - Company to Present additional positive phase 3 data for TX-004HR at the ISSWSH annual meeting - - Management to host co
Announces Fourth Quarter and Full Year 2015 Financial Results Company to Present additional positive phase 3 data for TX-004HR at the ISSWSH annual meeting - Management to host conference call today at 4:30 p.m. EST - RATON, Fla. - February 25, 2016 - TherapeuticsMD, Inc. (N
Read more →TXMDTherapeuticsMD Announces Positive Top-Line Results from its Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy (VVA) Treated with 25 mcg, 10 mcg or 4 mcg of TX-004HR Con
TherapeuticsMD, Inc. 8-K TherapeuticsMD Announces Positive Top-Line Results from its Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy (VVA) Treated with 25 mcg, 10 mcg or 4 mcg of TX-004HR Conference Call Scheduled for Today at 4:45 p.m. ET to Di
Read more →TXMDTXMD Overview November 2015 THER - 0063 11/ 15 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statem
TherapeuticsMD, Inc. TXMD Overview November 2015 THER - 0063 11/ 15 2 Forward - Looking Statements This presentation by TherapeuticsMD, Inc . (referred to as "we" and "our") may contain forward - looking statements . Forward - looking statements may include, but are not limited
Read more →TXMDTherapeuticsMD Announces Third Quarter 2015 Financial Results - Topline phase 3 data anticipated in fourth quarter for TX-004HR to treat symptoms of VVA - - Completed enrollment in phase 3 Replenish
TherapeuticsMD, Inc. 8-K Announces Third Quarter 2015 Financial Results Topline phase 3 data anticipated in fourth quarter for TX-004HR to treat symptoms of VVA - Completed enrollment in phase 3 Replenish Trial for first potential FDA-approved oral combination hormone therapy
Read more →TXMDTherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate - Study evaluates TX-001HR, first bio-identical combin
TherapeuticsMD Completes Enrollment in Phase 3 Clinical Trial of Bio-identical Oral Combination of Estradiol and Progesterone Product Candidate - Study evaluates TX-001HR, first bio-identical combination product candidate to treat vasomotor symptoms of menopause - BOCA RATON,
Read more →TXMDTXMD Overview August 2015 w w w . T h e r a p e u t i c s M D . c o m A Woman's Health Company THER - 0061 V3 8 /15 2 2 This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - look
TherapeuticsMD, Inc. 8-K 1 TXMD Overview August 2015 w w w . T h e r a p e u t i c s M D . c o m A Woman's Health Company THER - 0061 V3 8 /15 2 2 This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - looki
Read more →TXMDTherapeuticsMD Announces Second Quarter 2015 Financial Results - Completed Enrollment of 700 Patients in Phase 3 Rejoice Trial; Topline Data Anticipated in Fourth Quarter of 2015 - - Patient Recruit
TherapeuticsMD, Inc. 8-K Announces Second Quarter 2015 Financial Results in Fourth Quarter of 2015 - Management to Host Conference call Today at 4:30 p.m. EDT - 2015 - TherapeuticsMD, an innovative women's today announced its second quarter financial results for the period
Read more →TXMDTXMD Overview June 2015 w w w . T h e r a p e u t i c s M D . c o m A Woman's Health Company THER - 0060 V1 6/15 2 2 This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking
TherapeuticsMD, Inc. 8-K 1 TXMD Overview June 2015 w w w . T h e r a p e u t i c s M D . c o m A Woman's Health Company THER - 0060 V1 6/15 2 2 This presentation by TherapeuticsMD, Inc. (referred to as "we" and "our") may contain forward - looking statements. Forward - looking
Read more →TXMDTherapeuticsMD Completes Enrollment in The Rejoice Trial, a Phase 3 Clinical Trial of TX-004HR (estradiol in VagiCap TM ) - Topline Results Expected in Fourth Quarter of 2015
TherapeuticsMD, Inc. 8-K Completes Enrollment in The Rejoice Trial, a Phase 3 Clinical Trial of TX-004HR (estradiol in VagiCapTM) Topline Results Expected in Fourth Quarter of 2015 - RATON, Fla., June 9, 2015 - TherapeuticsMD Inc. (NYSE MKT: TXMD), an innovative women's healt
Read more →TXMDTherapeuticsMD announces first quarter 2015 financial results - First quarter product sales increased by 58 percent year over year - - Two phase 3 clinical trials advancing - - Management to host co
TherapeuticsMD, Inc. 8-K announces first quarter 2015 financial results First quarter product sales increased by 58 percent year over year - Two phase 3 clinical trials advancing - Management to host conference call today at 4:30 p.m. EDT - - TherapeuticsMD, Inc. TXMD), an
Read more →TXMDTherapeuticsMD appoints biopharmaceutical senior executives Angus C. Russell and J. Martin Carroll as independent directors
appoints biopharmaceutical senior executives C. Russell and J. Martin Carroll as independent directors RATON, Fla., March 18, 2015 - TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative women's healthcare company, announced today the appointment of two biopharmaceutical senior
Read more →TXMDTherapeuticsMD announces fourth quarter and full-year 2014 financial results - Current women's health product sales increased by 71 percent over prior year - - Cash balance strengthened following re
TherapeuticsMD. Inc. 8-K announces fourth quarter and full-year 2014 financial results Current women's health product sales increased by 71 percent over prior year - Cash balance strengthened following recent equity financing of $59.1 million in net proceeds - Management to h
Read more →TXMDInvestor Overview JANUARY 2015 w w w . T h e r a p e u t i c s M D . c o m 2 2 This presentation by TherapeuticsMD Inc. (referred to as "we" and "our") may contain "forward - looking statements" within the meaning of the
1 Investor Overview JANUARY 2015 w w w . T h e r a p e u t i c s M D . c o m 2 2 This presentation by TherapeuticsMD Inc. (referred to as "we" and "our") may contain "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Sectio
Read more →TXMDInvestor Overview NOVEMBER 2014 w w w . T h e r a p e u t i c s M D . c o m 2 2 This presentation by TherapeuticsMD Inc. (referred to as "we" and "our") may contain "forward - looking statements" within the meaning of th
TherapeuticsMD, Inc. 8-K 1 Investor Overview NOVEMBER 2014 w w w . T h e r a p e u t i c s M D . c o m 2 2 This presentation by TherapeuticsMD Inc. (referred to as "we" and "our") may contain "forward - looking statements" within the meaning of the Private Securities Litigation
Read more →TXMDTherapeuticsMD announces third quarter financial results - Company advances two phase 3 programs for novel hormone therapy product candidates - - Sales increased by 82 percent over prior year period
TherapeuticsMD, Inc. 8-K announces third quarter financial results Company advances two phase 3 programs for novel hormone therapy product candidates - Sales increased by 82 percent over prior year period - Management to host conference call today at 4:30 p.m. EST - 2014 - T
Read more →TXMDTHERAPEUTICSMD ANNOUNCES SECOND QUARTER 2014 FINANCIAL RESULTS - Company Significantly Strengthens Cash Balance with Recent Equity Offering - - Combination and VVA Hormone Therapy Programs Advancing
TherapeuticsMD, Inc. 8-K ANNOUNCES SECOND QUARTER 2014 FINANCIAL RESULTS Company Significantly Strengthens Cash Balance with Recent Equity Offering - Combination and VVA Hormone Therapy Programs Advancing on Schedule - Management to Host Conference Call Today at 4:30 p.m. EDT
Read more →TXMDNYSE MKT: TXMD Corporate Overview Q2 - 2014 COPYRIGHT 2014 by TherapeuticsMD - May 2014 This presentation includes forward - looking statements covered by the safe harbor provision of the Private Securities Litigation Re
TherapeuticsMD, Inc. 8-K NYSE MKT: TXMD Corporate Overview Q2 - 2014 COPYRIGHT 2014 by TherapeuticsMD - May 2014 This presentation includes forward - looking statements covered by the safe harbor provision of the Private Securities Litigation Reform Act of 1995 , including pred
Read more →TXMDTHERAPEUTICSMD REPORTS FIRST QUARTER 2014 RESULTS Management to Host Conference Call at 4:30 EDT Today Boca Raton, FL
TherapeuticsMD, Inc. 8-K THERAPEUTICSMD REPORTS FIRST QUARTER Management to Host Conference Call at Boca Raton, FL, May 5, 2014 - TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's health care company, ("TherapeuticsMD," the "Company," "we," or "our") today announced results f
Read more →TXMDNYSE MKT: TXMD Corporate Overview Q2 - 2014 COPYRIGHT 2014 by TherapeuticsMD This presentation includes forward - looking statements covered by the safe harbor provision of the Private Securities Litigation Reform Act of
NYSE MKT: TXMD Corporate Overview Q2 - 2014 COPYRIGHT 2014 by TherapeuticsMD This presentation includes forward - looking statements covered by the safe harbor provision of the Private Securities Litigation Reform Act of 1995 , including predictions, estimates, and other informa
Read more →TXMDTHERAPEUTICSMD ANNOUNCES LAUNCH OF SECONDARY OFFERING Boca Raton, FL
THERAPEUTICSMD ANNOUNCES LAUNCH OF SECONDARY OFFERING Boca Raton, FL, March 18, 2014 TherapeuticsMD, Inc. (NYSE MKT: TXMD) (the Company ) today announced the launch of an underwritten secondary public offering of 9,000,000 shares of its common stock. All shares will be offered
Read more →TXMDNYSE MKT: TXMD Corporate Overview Q1 - 2014 COPYRIGHT 2014 by TherapeuticsMD This presentation includes forward - looking statements covered by the safe harbor provision of the Private Securities Litigation Reform Act of
NYSE MKT: TXMD Corporate Overview Q1 - 2014 COPYRIGHT 2014 by TherapeuticsMD This presentation includes forward - looking statements covered by the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including predictions, estimates, and other informat
Read more →TXMDInvestor Relations: Dan Cartwright Lisa M. Wilson Chief Financial Officer In-Site Communications Tel: (561) 961-1930 Tel: (917) 543-9932 Dan.Cartwright@TherapeuticsMD.com lwilson@insitecony.com FOR IMMEDIATE RE
TherapeuticsMD, Inc. 8-K Contacts: Investor Relations: Dan Cartwright Lisa M. Wilson Chief Financial Officer In-Site Communications Tel: (561) 961-1930 Tel: (917) 543-9932 Dan.Cartwright@TherapeuticsMD.com lwilson@insitecony.com reports FOURTH quarter AND FULL-YEAR 2013 results
Read more →TXMDTHERAPEUTICSMD NAMES RANDALL S. STANICKY TO BOARD OF DIRECTORS Boca Raton, FL
TherapeuticsMD, Inc. 8-K THERAPEUTICSMD NAMES RANDALL S. STANICKY TO BOARD OF DIRECTORS Boca Raton, FL - December 18, 2013 - TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company ("TherapeuticsMD" or the "Company"), announced today that Randall S. Stanicky, CFA
Read more →TXMDTXMD Q3 2013 Earnings Conference Call
TherapeuticsMD, Inc. 8-K TXMD Q3 2013 Earnings Conference Wilson - In-Site Communications - Investor Relations for TherapeuticsMD, Inc. Cartwright - TherapeuticsMD, Inc. - Chief Financial Officer Finizio - TherapeuticsMD, Inc. - Co-Founder and Chief Executive Officer Samimy
Read more →TXMDDan Cartwright Investor Relations: Chief Financial Officer Lisa M. Wilson Tel: (561) 961-1930 In-Site Communications Dan.Cartwright@TherapeuticsMD.com Tel: (917) 543-9932 lwilson@insitecony.com FOR IMMEDIATE RE
TherapeuticsMD, Inc. 8-K Contacts: Dan Cartwright Investor Relations: Chief Financial Officer Lisa M. Wilson Tel: (561) 961-1930 In-Site Communications Dan.Cartwright@TherapeuticsMD.com Tel: (917) 543-9932 lwilson@insitecony.com reports THIRD quarter 2013 financial results M
Read more →TXMDTHERAPEUTICSMD, INC. PRESENTATION DATED OCTOBER 2013 TXMD Corporate Overview October 2013 COPYRIGHT 2013 by TherapeuticsMD This presentation includes forward - looking statements covered by the safe harbor provision of t
TXMD Corporate Overview October 2013 COPYRIGHT 2013 by TherapeuticsMD This presentation includes forward - looking statements covered by the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including predictions, estimates, and other information tha
Read more →TXMDDan Cartwright Investor Relations: Chief Financial Officer Lisa M. Wilson Tel: (561) 961-1900 In-Site Communications Dan.Cartwright@TherapeuticsMD.com Tel: (917) 543-9932 lwilson@insitecony.com FOR IMMEDIATE RE
Contacts: Dan Cartwright Investor Relations: Chief Financial Officer Lisa M. Wilson Tel: (561) 961-1900 In-Site Communications Dan.Cartwright@TherapeuticsMD.com Tel: (917) 543-9932 lwilson@insitecony.com THERAPEUTICSMD ANNOUNCES PRICING OF OFFERING OF COMMON STOCK Boca
Read more →TXMDDan Cartwright Chief Financial Officer Tel: (561) 961-1930 Dan.Cartwright@TherapeuticsMD.com Investor Relations: Lisa M. Wilson In-Site Communications Tel: (917) 543-9932 lwilson@insitecony.com FOR IMMEDIATE RE
THERAPEUTICSMD REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS Boca Raton, FL, August 6, 2013 - TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women's healthcare company focused on developing and commercializing products targeted exclusively for women, today announced financial results
Read more →TXMDDan Cartwright Chief Financial Officer Tel: (561) 961-1930 Dan.Cartwright@TherapeuticsMD.com Investor Relations: Lisa M. Wilson In-Site Communications Tel: (917) 543-993 lwilson@insitecony.com THERAPEUTICSMD IN
Contacts: Dan Cartwright Chief Financial Officer Tel: (561) 961-1930 Dan.Cartwright@TherapeuticsMD.com Investor Relations: Lisa M. Wilson In-Site Communications Tel: (917) 543-993 lwilson@insitecony.com THERAPEUTICSMD INVESTIGATIONAL NEW DRUG FILING ACCEPTED BY FDA Boca Rato
Read more →TXMDInvestor Presentation June 2013 COPYRIGHT 2013 by TherapeuticsMD
Investor Presentation June 2013 COPYRIGHT 2013 by TherapeuticsMD This presentation includes forward - looking statements covered by the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including predictions, estimates, and other information that mig
Read more →TXMDDan Cartwright Investor Relations: Chief Financial Officer Lisa M. Wilson Tel: (561) 961-1930 In-Site Communications Dan.Cartwright@TherapeuticsMD.com Tel: (917) 543-9932 lwilson@insitecony.com THERAPEUTICSMD E
TherapeuticsMD, Inc. 8-K Dan Cartwright Investor Relations: Chief Financial Officer Lisa M. Wilson Tel: (561) 961-1930 In-Site Communications Dan.Cartwright@TherapeuticsMD.com Tel: (917) 543-9932 lwilson@insitecony.com THERAPEUTICSMD ELECTS JULES A. MUSING TO BOARD OF DIR
Read more →TXMDTherapeuticsMD, Inc. 8-K Exhbit 99.1 .1 FOR IMMEDIATE RELEASE THERAPEUTICSMD ANNOUNCES TRADING OF ITS COMMON STOCK ON THE NYSE MKT UNDER SYMBOL "TXMD"
TherapeuticsMD, Inc. 8-K THERAPEUTICSMD ANNOUNCES TRADING OF ITS COMMON STOCK ON THE NYSE MKT UNDER SYMBOL "TXMD" BOCA RATON, FL-April 22, 2013-TherapeuticsMD, Inc. (OTCQB: TXMD) today announced that its common stock has been approved for listing on the NYSE MKT, the premier U
Read more →TXMDSYMBOL: TXMD
FOR IMMEDIATE RELEASE SYMBOL: TXMD March 15, 2013 TRADED: OTCQB TherapeuticsMD Announces Pricing of Public Offering of Common Stock BOCA RATON, Fla. - March 15, 2013 - (BUSINESS WIRE) - TherapeuticsMD, Inc. (TXMD) today announced the pricing of its previously announced under
Read more →TXMDUnless the context otherwise requires, the terms "Therapeutics," "TXMD," "Company," "we," "us," or "our" refer to TherapeuticsMD, Inc., a Nevada corporation, and its subsidiaries, vitaMedMD, LLC, a Delaware limited liabi
TherapeuticsMD, Inc. 8-K Unless the context otherwise requires, the terms "Therapeutics," "TXMD," "Company," "we," "us," or "our" refer to TherapeuticsMD, Inc., a Nevada corporation, and its subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed, and Boca
Read more →TXMDTherapeuticsMD , Inc., 8-K FOR IMMEDIATE RELEASE SYMBOL: TXMD
TherapeuticsMD , Inc., 8-K FOR IMMEDIATE RELEASE SYMBOL: TXMD August 7, 2012 TRADED: OTCQB THERAPEUTICSMD, INC. HAS IND FILING ACCEPTED BY FDA FOR IMMEDIATE RELEASE - August 7, 2012 - Boca Raton, FL - TherapeuticsMD , Inc. [OTCQB: TXMD], parent company of vitaMedMD , LLC ("vit
Read more →TXMDConsent of Independent Registered Public Accounting Firm The Board of Directors and Stockholders VitaMedMD, LLC Boca Raton, Florida We consent to the use of our Report of Independent Registered Public Accounting Firm dat
TherapeuticsMD, Inc. 8-K Consent of Independent Registered Public Accounting Firm The Board of Directors and Stockholders We consent to the use of our Report of Independent Registered Public Accounting Firm dated July 15, 2011 on our audit of the financial statements of VitaMe
Read more →TXMDSPECTRUM HEALTH NETWORK, INC. INDEX TO FINANCIAL STATEMENTS Financial Statements: Report of Independent Registered Public Accounting Firm Balance Sheet as of
SPECTRUM HEALTH NETWORK, INC. INDEX TO FINANCIAL STATEMENTS Financial Statements: Report of Independent Registered Public Accounting Firm Balance Sheet as of December 31, 2009 Statements of Operations for the Period October 21, 2009 (Inception) through December 31, 2009
Read more →TXMDAMERICA S MINORITY HEALTH NETWORK, INC. INDEX TO FINANCIAL STATEMENTS Financial Statements: Report of Independent Registered Public Accounting Firm Balance Sheet as of
AMERICA S MINORITY HEALTH NETWORK, INC. INDEX TO FINANCIAL STATEMENTS Financial Statements: Report of Independent Registered Public Accounting Firm Balance Sheet as of June 30, 2009 (Unaudited) Statements of Operations for the Period April 2, 2009 (Inception) through June 30, 2
Read more →TXMDCroff Enterprises, Inc. Agrees to Merge with America's Minority Health Network, Inc. Los Angeles, CA -- (BUSINESS WIRE)
Enterprises, Inc. Agrees to Merge with America's Minority Health Network, Angeles, CA -- (BUSINESS WIRE) - July 9, 2009 - Croff Enterprises, Inc. (OTCBB: COFF.OB) announced today that it has signed a definitive reorganization and merger agreement with America's Minority Healt
Read more →TXMDCroff announces Common Share Sale and Dividend DENVER, CO - 06/12/2008 -- Croff Enterprises, Inc. (OTCBB: COFF)announced today that the members of the Board of Directors including the Company's Chairman and President hav
announces Common Share Sale and Dividend CO - 06/12/2008 -- Croff Enterprises, Inc. (OTCBB: COFF)announced today that the members of the Board of Directors including the Company's Chairman and President have entered into agreements to sell all of their shares in Croff Enterpri
Read more →Competitive Position
How TXMD ranks across every disease it competes inCompetitive Position is a premium feature
See how TXMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial